Inhibitors of β-nerve growth factor (NGF) have impressive effects in reducing musculoskeletal pain, but have also been associated with adverse events of unclear aetiology. Several studies in the past year have sought to clarify the relative benefits and risks of anti-NGF treatment.
This is a preview of subscription content, log in via an institution to check access.
References
Eibib, J., Strasser, B. C. & Ross, G. M. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem. Int. 6, 1266–1275 (2012).
Schnitzer, T. J. & Marks, J. A. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip and knee. Osteoarthritis Cartilage 23 (Suppl. 1), S8–S17 (2015).
Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521–1531 (2010).
Hochberg, M. C. et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 68, 382–391 (2016).
Maloney, J. et al. Efficacy and safety of fasinumab for osteoarthritic pain in patients with moderate to severe osteoarthritis of the knees or hips [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 295 (2016).
Regeneron Pharmaceuticals. Regeneron and Teva provide update on fasinumab clinical development programs. PR Newswire http://www.prnewswire.com/news-releases/regeneron-and-teva-provide-update-on-fasinumab-clinical-development-programs-300345603.html (2016).
Prencipe, G. et al. Nerve growth factor downregulates inflammatory response in human monocytes through TrkA. J. Immunol. 192, 3345–3354 (2014).
Krock, E. et al. Nerve growth factor is regulated by Toll-like receptor 2 in human intervertebral discs. J. Biol. Chem. 291, 3541–3551 (2016).
Wirz, S. A., Tobias, P. S., Ulevitch, R. J., Aribibe, L. & Bartfai, T. TLR2 is required for the altered transcription of p75NGF receptors in Gram positive infection. Neurochem. Res. 31, 297–301 (2006).
Jiang, Y. et al. Nerve growth factor promotes TLR4 signaling-induced maturation of human dendritic cells in vitro through inducible p75NTR 1. J. Immunol. 179, 6297–6304 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.E.L. declares that she is a consultant to and advisory board member for Regeneron. M.C. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Lane, N., Corr, M. Anti-NGF treatments for pain — two steps forward, one step back?. Nat Rev Rheumatol 13, 76–78 (2017). https://doi.org/10.1038/nrrheum.2016.224
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.224
- Springer Nature Limited
This article is cited by
-
Targeting aging and age-related diseases with vaccines
Nature Aging (2024)
-
Classification of four distinct osteoarthritis subtypes with a knee joint tissue transcriptome atlas
Bone Research (2020)
-
EZH2 inhibition reduces cartilage loss and functional impairment related to osteoarthritis
Scientific Reports (2020)
-
RIPK1 suppresses apoptosis mediated by TNF and caspase-3 in intervertebral discs
Journal of Translational Medicine (2019)
-
Real-time simultaneous recording of electrophysiological activities and dopamine overflow in the deep brain nuclei of a non-human primate with Parkinson’s disease using nano-based microelectrode arrays
Microsystems & Nanoengineering (2018)